April 2, 2026 — Iterative Health and US Heart & Vascular (USHV) have announced a strategic partnership to advance research through community-based innovation in cardiovascular care.
"Clinical research is one of the most powerful ways we expand access, improve patient outcomes, and shape the future of cardiovascular care," said Robbie Allen, chief executive officer of US Heart & Vascular. "By partnering with Iterative Health, we are strengthening our ability to bring innovative therapies directly into the communities we serve. This collaboration ensures our physicians and patients have access to leading-edge trials while allowing US Heart & Vascular to remain focused on delivering exceptional, physician-led care."
Under the agreement, USHV research sites will join Iterative Health’s global site network, which now spans over 100 sites across three continents. The companies share a commitment to advancing clinical research as a driver of care innovation, and this collaboration represents a major milestone for both organizations, strengthening USHV's leadership in community-based cardiovascular research and expanding Iterative Health's multispecialty focus beyond GI, hepatology, and obesity into cardiology.
USHV clinical research sites will gain access to Iterative Health's centralized operational backbone, providing end-to-end support across clinical research operations, services, business development, technology innovation, and corporate functions. The strategic partnership reduces operational complexity and unlocks growth potential for USHV research sites while enabling all USHV physicians to expand access to cutting-edge therapies to the thousands of patients they serve annually.
"Innovation in cardiovascular medicine shouldn't be limited to a few academic centers," said Thomas Waggoner, DO, MD, RPVI, FACC, FSCAI, FSVM, RPVI, Structural Cardiologist and Medical Director for Clinical Research at Pima Heart & Vascular, and USHV Physician Champion for Clinical Research. "By expanding community-based research across USHV, we're ensuring more patients have access to clinical trials and breakthrough therapies close to home, where trusted relationships with their physicians already exist."
This alliance reinforces Iterative Health's standing as the definitive research partner across specialized therapeutic areas, now spanning GI, hepatology, obesity, and cardiovascular care. Trusted by many of the nation's leading provider organizations and biopharma sponsors, Iterative Health's global site network delivers industry-leading trial performance, accelerating life-changing therapies to market at scale.
"Entering cardiology through our strategic partnership with US Heart & Vascular is a defining moment for Iterative Health and reflects the strength of our site-serving model," said Jonathan Ng, founder and CEO of Iterative Health. "Together, we are ensuring that thousands of patients have access to the newest available therapies, and that sponsors have a credible, high-performing partner to accelerate cardiovascular trial success."
For more information, visit www.iterative.health and https://usheartandvascular.com/.
April 26, 2024 
